­
­
­
­

Inventi Impact: Gastroenterology

Articles

  • Inventi:hgst/28026/19
    A New Immunofluorescence Assay for Fecal Calprotectin Distinguishes Inflammatory Bowel\nDisease from Functional Bowel Disease
    Research 2019 : April - June
    Lixia Xu, Peisi Rao, Xin Liu, Zhirong Zeng

    Aims: To investigate the diagnostic value of fecal calprotectin (FC) determined\nby a new immunofluorescence assay-fluorescence enzyme immunoassay\n(FEIA) in patient with inflammatory bowel disease (IBD) or functional\nbowel disease, compared with the typical ELISA kit. Methods: FC was determined\nsimultaneously by FEIA and an ELISA kit in 26 patients with functional\nbowel disease and 77 patients with IBD. We compared the difference of\nFC levels between patients with IBD and patients with functional bowel disease.\nReceiver operating characteristics curve (ROC) was constructed to obtain\nthe optimal cut-off value of FC for distinguishing IBD from functional\nbowel disease and the corresponding sensitivity and specificity. Results: The\nmedian FC levels of patients with IBD in clinical active stage or clinical remission\nstage was significantly higher than that of patients with functional\nbowel disease. The median FC levels of patients with IBD in clinical active\nstage, IBD in clinical remission stage and functional bowel disease were as\nfollow: 699.91.................

    How to Cite this Article
    CC Compliant Citation: Xu, L.X., Rao, P.S., Liu, X. and Zeng, Z.R. (2018) A New Immunofluorescence\nAssay for Fecal Calprotectin Distinguishes Inflammatory Bowel Disease from Functional Bowel\nDisease. Open Journal of Gastroenterology, 8, DOI: 10.4236/ojgas.2018.811042, http://\ncreativecommons.org/licenses/by/4.0/.
    Download Full Text